Business Description
Autolus Therapeutics PLC
NAICS : 325412
SIC : 2834
ISIN : US05280R1005
Compare
Compare
Traded in other countries / regions
AUTL.USA6A3A.Germany IPO Date
2018-06-22Description
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 6.04 | |||||
| Equity-to-Asset | 0.51 | |||||
| Debt-to-Equity | 0.22 | |||||
| Debt-to-EBITDA | -0.34 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -1.55 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -1.5 | |||||
| 3-Year EBITDA Growth Rate | 19.1 | |||||
| 3-Year EPS without NRI Growth Rate | 18.3 | |||||
| 3-Year FCF Growth Rate | 22.6 | |||||
| 3-Year Book Growth Rate | -32.7 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 9.89 | |||||
| 9-Day RSI | 17.16 | |||||
| 14-Day RSI | 26.16 | |||||
| 6-1 Month Momentum % | 75.27 | |||||
| 12-1 Month Momentum % | 56.37 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 8.65 | |||||
| Quick Ratio | 8.65 | |||||
| Cash Ratio | 7.49 | |||||
| Days Sales Outstanding | 29.62 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -56.7 | |||||
| Shareholder Yield % | -2.32 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -2223.71 | |||||
| Net Margin % | -2071.61 | |||||
| ROE % | -66.24 | |||||
| ROA % | -39.18 | |||||
| ROIC % | -170.05 | |||||
| ROC (Joel Greenblatt) % | -259.26 | |||||
| ROCE % | -44.6 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 34.37 | |||||
| PB Ratio | 1.8 | |||||
| Price-to-Tangible-Book | 1.8 | |||||
| EV-to-EBIT | -0.95 | |||||
| EV-to-EBITDA | -0.99 | |||||
| EV-to-Revenue | 20.02 | |||||
| EV-to-Forward-Revenue | 607.04 | |||||
| EV-to-FCF | -1.05 | |||||
| Price-to-Net-Current-Asset-Value | 3.08 | |||||
| Price-to-Net-Cash | 4.84 | |||||
| Earnings Yield (Greenblatt) % | -105.26 |
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:AUTL
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Autolus Therapeutics PLC Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 7.486 | ||
| EPS (TTM) ($) | -1.19 | ||
| Beta | 1.05 | ||
| Volatility % | 106.04 | ||
| 14-Day RSI | 26.16 | ||
| 14-Day ATR ($) | 0.176197 | ||
| 20-Day SMA ($) | 2.963 | ||
| 12-1 Month Momentum % | 56.37 | ||
| 52-Week Range ($) | 1.6 - 3.54 | ||
| Shares Outstanding (Mil) | 173.68 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Autolus Therapeutics PLC Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Autolus Therapeutics PLC Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Autolus Therapeutics PLC Frequently Asked Questions
What is Autolus Therapeutics PLC(AUTL)'s stock price today?
The current price of AUTL is $2.37. The 52 week high of AUTL is $3.54 and 52 week low is $1.60.
When is next earnings date of Autolus Therapeutics PLC(AUTL)?
The next earnings date of Autolus Therapeutics PLC(AUTL) is 2023-11-03 Est..
Does Autolus Therapeutics PLC(AUTL) pay dividends? If so, how much?
Autolus Therapeutics PLC(AUTL) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers